DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities
Y Abuetabh, HH Wu, C Chai, H Al Yousef… - … & molecular medicine, 2022 - nature.com
Antitumor therapeutic strategies that fundamentally rely on the induction of DNA damage to
eradicate and inhibit the growth of cancer cells are integral approaches to cancer therapy …
eradicate and inhibit the growth of cancer cells are integral approaches to cancer therapy …
DNA damage checkpoint kinases in cancer
DNA damage response (DDR) pathway prevents high level endogenous and environmental
DNA damage being replicated and passed on to the next generation of cells via an …
DNA damage being replicated and passed on to the next generation of cells via an …
Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers
Radiotherapy is used in the treatment of approximately 50% of all malignancies including
gastrointestinal cancers. Radiation can be given prior to surgery (neoadjuvant radiotherapy) …
gastrointestinal cancers. Radiation can be given prior to surgery (neoadjuvant radiotherapy) …
ATR/CHK1 inhibitors and cancer therapy
The cell cycle checkpoint proteins ataxia-telangiectasia-mutated-and-Rad3-related kinase
(ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of …
(ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of …
[HTML][HTML] Progress towards a clinically-successful ATR inhibitor for cancer therapy
The DNA damage response (DDR) is now known to play an important role in both cancer
development and its treatment. Targeting proteins such as ATR (Ataxia telangiectasia …
development and its treatment. Targeting proteins such as ATR (Ataxia telangiectasia …
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
The DNA damage response (DDR) machinery is responsible for detecting DNA damage,
pausing the cell cycle and initiating DNA repair. Ataxia telangiectasia and Rad3-related …
pausing the cell cycle and initiating DNA repair. Ataxia telangiectasia and Rad3-related …
Targeting DNA repair pathway in cancer: Mechanisms and clinical application
M Wang, S Chen, D Ao - MedComm, 2021 - Wiley Online Library
Over the last decades, the growing understanding on DNA damage response (DDR)
pathways has broadened the therapeutic landscape in oncology. It is becoming increasingly …
pathways has broadened the therapeutic landscape in oncology. It is becoming increasingly …
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy
Chemoresistance, radioresistance, and the challenge of achieving complete resection are
major driving forces in the search for more robust and targeted anticancer therapies …
major driving forces in the search for more robust and targeted anticancer therapies …
An overview of the recent development of anticancer agents targeting the HIF-1 transcription factor
Y Shirai, CCT Chow, G Kambe, T Suwa, M Kobayashi… - Cancers, 2021 - mdpi.com
Simple Summary As hypoxia-inducible factor 1 (HIF-1) is recognized as a target for cancer
therapy, extensive efforts have been devoted to develo** its inhibitors. We provide an …
therapy, extensive efforts have been devoted to develo** its inhibitors. We provide an …
Malignant pheochromocytoma–paraganglioma: pathogenesis, TNM staging, and current clinical trials
Malignant pheochromocytoma–paraganglioma: pathogenesis, TNM... : Current Opinion in
Endocrinology, Diabetes and Obesity Malignant pheochromocytoma–paraganglioma …
Endocrinology, Diabetes and Obesity Malignant pheochromocytoma–paraganglioma …